CK Group is delighted to announce that CK Aspire has been named a finalist in the EyeforPharma awards, in the ‘Most Valuable Patient Initiative’ category, for their collaboration with GSK on the Salford Lung Study.
The finalists of this award are all innovative projects that have been designed to deliver tangible patient improvements, both in the long and short term. The finalists have been selected due to their ability to demonstrate real understanding of the patient requirements prior to implementation and have made an exceptionally positive impact on their intended customer.
The SLS study, was the world’s first digitally enhanced Randomised Controlled Trial and adopted some pioneering approaches to gain access too hard to reach audiences. A range of strategies were employed to ensure the data submitted included a broad and inclusive population.
